Understanding the stock market can be a challenging endeavor, yet it offers vast potential for substantial gains, particularly when it comes to penny stocks. Penny stocks, which typically trade below $5 per share, offer an accessible route to market participation, often piquing the interest of investors seeking higher returns with lower capital.

Looking for Undervalued Penny Stocks? Use These Tips

Take a look at these 3 industries to find penny stocks in The post Penny Stock Investing, 3 High-Growth Industries to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stock Investing, 3 High-Growth Industries to Watch

Bioventus Inc. (NASDAQ:BVS ) Q1 2023 Earnings Conference Call May 16, 2023 5:00 PM ET Company Participants Dave Crawford - VP, IR Tony Bihl - CEO Mark Singleton - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Kyle Rose - Canaccord Drew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to the Bioventus Inc. First Quarter 2023 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Dave Crawford, Vice President, Investor Relations.

Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript

DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May 11, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

BVS, BFAM and ESTE have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2023.

New Strong Sell Stocks for April 5th

Bioventus Inc. (NASDAQ:BVS ) Q4 2022 Earnings Conference Call March 31, 2023 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Ken Reali - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Caitlin Cronin - Canaccord Operator Good day. And welcome to the Bioventus Incorporated Fourth Quarter 2022 Earnings Conference Call.

Bioventus Inc. (BVS) Q4 2022 Earnings Call Transcript

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.